Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

, UA

Under Armour; also tag UAA

$38.35

0.57 (1.51%)

10:25
10/10/16
10/10
10:25
10/10/16
10:25

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MYL

Mylan

$35.94

-0.9 (-2.44%)

UA

Under Armour; also tag UAA

$38.35

0.57 (1.51%)

DE

Deere

$88.14

1.84 (2.13%)

AGCO

Agco

$52.27

2.07 (4.12%)

DOW

Changed to DWDP

$53.67

0.68 (1.28%)

EXEL

Exelixis

$12.95

-0.23 (-1.75%)

  • 10

    Oct

  • 10

    Oct

  • 13

    Oct

  • 25

    Oct

  • 26

    Oct

  • 09

    Nov

  • 16

    Nov

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
UBSW
10/10/16
NO CHANGE
Target $60
UBSW
Buy
UBS remains constructive on Mylan despite governance controversy
UBS analyst Marc Goodman said he remains constructive on Mylan despite the controversy surrounding its corporate governance. Goodman cited the company's ability to execute, its surprise announcement of a EpiPen Medicaid lawsuit settlement and its updated guidance, which was better than feared. Goodman reiterated his Buy rating and lowered his price target to $60 from $66 on Mylan shares.
UA Under Armour; also tag UAA
$38.35

0.57 (1.51%)

10/10/16
WELS
10/10/16
UPGRADE
WELS
Outperform
Under Armour upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Tom Nikic upgraded Under Armour to Outperform saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales reacceleration over the next 12-18 months. The analyst believes Under Armour's growth story is intact heading into 2017 and that its inventory levels are improving. Nikic raised his price target range for the shares to $44-$46 from $38-$42.
10/06/16
ROTH
10/06/16
NO CHANGE
Target $22.5
ROTH
Buy
Under Armour deal should drive MINDBODY platform exposure, says Roth Capital
Roth Capital analyst Darren Aftahi notes that Under Armour (UA) has announced integration of its popular MyFitnessPal application with MINDBODY's (MB) platform. The partnership will enable users to search, book and pay for fitness classes directly on the app, which the analyst believes should be beneficial to MINDBODY's subscribers and its business in general. While it is unclear whether the deal with Under Armour is exclusive, the analyst believes it could open the door for MINDBODY to strike similar deals with other large fitness apparel companies like Nike (NKE) and its Nike+ mobile application. He reiterates a Buy rating and $22.50 price target on MINDBODY's shares.
09/30/16
GUGG
09/30/16
INITIATION
Target $50
GUGG
Buy
Under Armour initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated Under Armour with a Buy and a $50 price target as he expects growth in the strong activewear/athletic category to continue and believes a premium multiple is warranted.
09/13/16
09/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chevron (CVX) initiated with an Outperform at BMO Capital. 2. AB InBev (BUD) initiated with a Buy at Jefferies. 3. Altria Group (MO) and Reynolds American (RAI) were initiated with a Buy at Citi while the firm initiated Philip Morris (PM) with a Neutral. 4. Under Armour (UA) initiated with a Neutral at Nomura. 5. Xerox (XRX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DE Deere
$88.14

1.84 (2.13%)

09/07/16
09/07/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Navistar (NAV) initiated with a Hold at Deutsche Bank. 2. Barrick Gold (ABX) initiated with a Sell at Berenberg while the firm initiated Randgold (GOLD), Kinross Gold (KGC), and Goldcorp (GG) with a Hold. 3. 3. After the close on Tuesday, Deutsche Bank analysts Nicole DeBlase, Saree Boroditsky, and Kevin Marek initiated the U.S. Machinery group with a "cautious view." Oshkosh (OSK), Caterpillar (CAT), and Wabtec (WAB) were initiated with Buy ratings at Deutsche Bank, while the firm initiated Cummins (CMI) and CNH Industrial (CNHI) with Sell ratings. The firm also initiated Deere (DE), AGCO (AGCO), Terex (TEX), PACCAR (PCAR), WABCO (WBC), and United Rentals (URI) with Hold ratings. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/16
BARD
09/14/16
NO CHANGE
Target $86
BARD
Neutral
Baird remains cautious on Deere after survey of ag equipment dealers
Baird analyst Mig Dobre remains cautious on Deere shares following a "stubbornly weak" agricultural equipment orders survey of dealers. The report pointed to a third year of equipment early order program declines, with declines only marginally improved from last year. Dobre feels the potential magnitude of decline in 2017 could surprise negatively. Dobre maintained his Neutral rating and lowered his price target to $86 from $90 on Deere shares.
10/10/16
WELS
10/10/16
UPGRADE
WELS
Outperform
Deere upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Andrew Casey upgraded Deere to Outperform after hosting investor meetings with management. After three years of global farm equipment demand decline, the market may be bottoming and turning positive, Casey tells investors in a research note. Deere is seeing improvement in Brazil, parts of Europe, Ukraine, Russia, India and other regions, the analyst contends. He raised his price target range for the shares to $100-$103 from $85-$88.
10/10/16
WELS
10/10/16
UPGRADE
WELS
Outperform
AGCO upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Andrew Casey upgraded AGCO (AGCO) to Outperform saying that after three years of demand decline, the company will benefit from an anticipated bottoming in global farm equipment demand. More favorable indications in Brazil and Europe should benefit approximately 70% of the company's revenue mix, Casey tells investors in a research note. He raised his price target range for the shares to $60-$63 from $46-$49. The analyst this morning also upgraded Deere (DE) to Outperform.
AGCO Agco
$52.27

2.07 (4.12%)

09/06/16
DBAB
09/06/16
INITIATION
Target $54
DBAB
Hold
AGCO initiated with a Hold at Deutsche Bank
Target $54.
07/25/16
PIPR
07/25/16
DOWNGRADE
Target $5
PIPR
Underweight
CNH Industrial downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Brett Wong downgraded CNH Industrial (CNHI) to Underweight on expectations the current agriculture downturn is going to persist in 2017 for a fourth consecutive year. Growing conditions have been "extremely favorable," making another large U.S. corn crop this year very likely, Wong tells investors in a research note. He expects grain prices to remain weak and lowered his price target for CNH shares to $5 from $7. Wong this morning also downgraded Deere (DE) and AGCO (AGCO) to Underweight.
DOW Changed to DWDP
$53.67

0.68 (1.28%)

10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Dow Chemical upgraded to Buy from Neutral at Citi
Citi analyst P.J. Juvekar upgraded Dow Chemical (DOW) to Buy from Hold citing the opportunity presented by the proposed merger with DuPont (DD). The analyst also upgraded DuPont to Buy from Hold this morning.
10/10/16
UBSW
10/10/16
UPGRADE
Target $62
UBSW
Buy
Dow Chemical upgraded to Buy from Neutral at UBS
UBS analyst John Roberts upgraded Dow Chemical (DOW) to Buy saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." The analyst sees $3B in potential cost savings and expects improving cash flow. Roberts raised his price target for the shares to $62 from $53.
10/03/16
10/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) and DuPont (DD) were upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing he opportunity presented by the proposed merger. 2. Freeport McMoRan (FCX), Barrick Gold (ABX), and Pan American Silver (PAAS) were upgraded to Buy from Hold at Deutsche Bank. 3. LogMeln (LOGM) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the pending merger with Citrix's (CTXS) divested GoTo assets creates a "great new opportunity." 4. Halliburton (HAL) upgraded to Buy from Hold at Societe General. 5. Coty (COTY) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying she believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Citi upgrades Dow and DuPont, says DowDuPont could be 'stock to own' in 2017
As previously reported, Citi analyst P.J. Juvekar upgraded shares of both Dow Chemical (DOW) and DuPont (DD), each to Buy from Hold, citing their "massive" cost-cutting opportunity after their proposed merger goes through as well as the potential for upside to the companies' stated $3B synergy target. If their deal gets completed, the combined Dow-DuPont would "be the stock to own in 2017," said Juvekar, who raised the firm's price target on DuPont shares to $76 from $72 and increased the target for Dow shares to $59 from $55.
EXEL Exelixis
$12.95

-0.23 (-1.75%)

09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink says ESMO raises confidence in potential label expansions at Exelixis
Following several oral and poster presentations this weekend at the ESMO cancer meeting, Leerink analyst Michael Schmidt said he has greater confidence regarding several potential label expansion opportunities for Exelixis' two products, Cabometyx and Cotellic. Cabometyx is "very well positioned" to capture significant market share and consensus expectations for Cotellic are only modest, believes Schmidt, who keeps an Outperform rating on Exelixis shares.
10/10/16
PIPR
10/10/16
UPGRADE
PIPR
Overweight
Exelixis upgraded to Overweight from Neutral at Piper Jaffray
10/10/16
PIPR
10/10/16
UPGRADE
Target $21
PIPR
Overweight
Exelixis upgraded to Overweight after trial success at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff upgraded Exelixis to Overweight from Neutral after the company reported Phase II CABOSUN data in 157 front-line metastatic Renal Cell Carcinoma patients. The data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use, Tenthoff tells investors in a research note. The analyst raised his price target for the shares to $21 from $8.

TODAY'S FREE FLY STORIES

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.